Basilea Secures $30M BARDA Boost for Phase 3 Antifungal Development — Basilea Pharmaceutica International Ltd, Allschwil

Event summary

$30M funding from BARDA under existing agreement for fosmanogepix Phase 3 development.
Total BARDA commitment now $123M, with potential non-dilutive funding up to $268M over 12 years.
Fosmanogepix targets invasive fungal infections including aspergillosis and candidiasis.
Phase 3 FAST and FORWARD studies ongoing for candidemia and invasive mold infections.

The big picture

Basilea's $30M funding injection underscores the strategic importance of novel antifungals in addressing drug-resistant infections, a growing global health challenge. The BARDA partnership reflects heightened government focus on biodefense and pandemic preparedness, particularly for immunocompromised patient populations. With potential non-dilutive funding reaching $268M, this deal positions Basilea as a key player in the antifungal space, though execution risks remain tied to clinical trial outcomes.

What we're watching

Clinical Milestones: The pace at which fosmanogepix Phase 3 studies (FAST and FORWARD) progress through enrollment and interim results.
Regulatory Pathway: Whether the Fast Track and Orphan Drug designations will accelerate FDA approval timelines for fosmanogepix.
Funding Utilization: How Basilea allocates the additional $30M to support not just fosmanogepix but also BAL2062 development under the BARDA agreement.